Clara Biotech named investor Joseph Gentile to its board following the closure of a $1.5 million seed round.
“The reason this is critical to our business is because the people we’ve brought onboard have deep connections in biotech and the ecosystem,” CEO Jim West III told the 4thEst8. “As well as a foothold into the Boston ecosystem where alot of our customers exist and that brings on expertise to help us build out a better product and business.”
Jim West III, Clara Biotech CEO
Clara Biotech’s technology isolates specific cellular markers (exosomes) from very small fluid samples enabling liquid biopsy for the very early detection of many diseases like cancer and Alzheimer’s. These same markers can also be turned into a precision medicine drug delivery platform. CEO Jim West III did not respond to voice mail and PM’s requesting comment for this article.
The company also announced the addition of three members to its advisory board:
- Michael Singer, MD, PhD – co-founder and CSO of Cartesian Therapeutics; Asst. Prof. Med, Yale Univ.
- Martin Madaus, DVM, PhD – past CEO of Roche Diagnostics and Milipore.
- Rick Ryan, PhD, MBA – general partner, Cultivation Capital Life Sciences.
The company was co-founded by West and University of Florida assistant professor Mei He, Ph.D. in June of 2018. It is headquartered in Lawrence, KS and claims eight employees on it’s LinkedIn page. In April, 2021 it was a presenting company at InvestMidwest.
Links:
Clara Biotech
On the 4thEst8:
